Biography
Professional Summary
Education & Certifications
- Fellowship: University of Colorado Denver Hematology and Oncology Fellowship (2005) CO
- Fellowship, Acute leukemia, Princess Margaret Hospital - University of Toronto (2006)
- Residency: University of Colorado Health Science Center (2002) CO
- Internship: University of Connecticut Health Center (2000) CT
- Medical Education: University Federal Do Parana (1998) Brazil
Administrative Appointments
- Acute Leukemia Panel Member, Southwest Oncology Group (SWOG) (2007 - 2016)
- Director, Stanford Hospital Hematology Inpatient service (2011 - 2016)
- Director, Director of Infusion Services (ITA) (2015 - 2016)
- Panel member adult oncology committee, National comprehensive cancer network (2010 - 2016)
- Panel Member Multiple Myeloma Committee, National Comprehensive Cancer Network (2007 - 2011)
Publications
-
Reversible high-output cardiac failure, an unusual marker of disease status in multiple myeloma
Kohrt, H., Logan, A., Temmins, C., Witteles, R., Liedtke, M., & Medeiros, B. (2008). Reversible high-output cardiac failure, an unusual marker of disease status in multiple myeloma. LEUKEMIA & LYMPHOMA, 49(3), 581–85. -
Comparing Apples and Oranges in Normal Karyotype Acute Myeloid Leukemia
Medeiros, B. C. (2009). Comparing Apples and Oranges in Normal Karyotype Acute Myeloid Leukemia. JOURNAL OF CLINICAL ONCOLOGY, 27(3), 474–474. -
Complete remission of primary plasma cell leukemia with bortezomib, doxorubicin, and dexamethasone: a case report.
Chan, S. M., George, T., Cherry, A. M., & Medeiros, B. C. (2009). Complete remission of primary plasma cell leukemia with bortezomib, doxorubicin, and dexamethasone: a case report. Cases Journal, 2(1), 121-? -
Role of CEBPA in Normal Karyotype Acute Myeloid Leukemia
Medeiros, B. C. (2009). Role of CEBPA in Normal Karyotype Acute Myeloid Leukemia. JOURNAL OF CLINICAL ONCOLOGY, 27(12), 2105–2105. -
Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia
Medeiros, B. C. (2009). Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia. NEW ENGLAND JOURNAL OF MEDICINE, 360(17), 1787–1787. -
Molecular stratification of patients with normal karyotype acute myeloid leukemia based on initial assessment of FLT3-internal tandem duplication status at first complete remission
Medeiros, B. C., Gotlib, J., & Zehnder, J. (2009). Molecular stratification of patients with normal karyotype acute myeloid leukemia based on initial assessment of FLT3-internal tandem duplication status at first complete remission. LEUKEMIA & LYMPHOMA, 50(5), 851–53. -
Thalidomide-induced pneumonitis in a patient with plasma cell leukemia: No recurrence with subsequent lenalidomide therapy
Pretz, J., & Medeiros, B. C. (2009). Thalidomide-induced pneumonitis in a patient with plasma cell leukemia: No recurrence with subsequent lenalidomide therapy. AMERICAN JOURNAL OF HEMATOLOGY, 84(10), 698–699. -
Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2)
Medeiros, B. C., Kohrt, H. E., Arber, D. A., Bangs, C. D., Cherry, A. M., Majeti, R., … Alizadeh, A. A. (2010). Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2). LEUKEMIA RESEARCH, 34(5), 594–97. -
Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience
Medeiros, B. C., Othus, M., Fang, M., Roulston, D., & Appelbaum, F. R. (2010). Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. BLOOD, 116(13), 2224–28. -
Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: A diagnostic challenge
Arredondo, A. R., Gotlib, J., Shier, L., Medeiros, B., Wong, K., Cherry, A., … George, T. I. (2010). Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: A diagnostic challenge. AMERICAN JOURNAL OF HEMATOLOGY, 85(8), 600–606. -
Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience
Kohrt, H. E., Patel, S., Ho, M., Owen, T., Pollyea, D. A., Majeti, R., … Medeiros, B. C. (2010). Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience. AMERICAN JOURNAL OF HEMATOLOGY, 85(11), 877–81. -
Plasma cell leukemia: concepts and management.
Liedtke, M., & Medeiros, B. C. (2010). Plasma cell leukemia: concepts and management. Expert Review of Hematology, 3(5), 543–49. -
Acute myeloid leukaemia in the elderly: a review
Pollyea, D. A., Kohrt, H. E., & Medeiros, B. C. (2011). Acute myeloid leukaemia in the elderly: a review. BRITISH JOURNAL OF HAEMATOLOGY, 152(5), 524–42. -
Unfavorable-risk cytogenetics in acute myeloid leukemia
Hong, W.-J., & Medeiros, B. C. (2011). Unfavorable-risk cytogenetics in acute myeloid leukemia. EXPERT REVIEW OF HEMATOLOGY, 4(2), 173–84. -
Cytarabine Dose for Acute Myeloid Leukemia
Medeiros, B. C., Othus, M., & Appelbaum, F. R. (2011). Cytarabine Dose for Acute Myeloid Leukemia. NEW ENGLAND JOURNAL OF MEDICINE, 364(22), 2167–2168. -
Microfluidic purification and analysis of hematopoietic stem cells from bone marrow
Schirhagl, R., Fuereder, I., Hall, E. W., Medeiros, B. C., & Zare, R. N. (2011). Microfluidic purification and analysis of hematopoietic stem cells from bone marrow. LAB ON A CHIP, 11(18), 3130–35. -
Impact of residual normal metaphases in core binding factor acute myeloid leukemia
Medeiros, B. C., Othus, M., Fang, M., Appelbaum, F. R., & Estey, E. H. (2012). Impact of residual normal metaphases in core binding factor acute myeloid leukemia. CANCER, 118(9), 2420–23. -
Treatment advances have not improved the early death rate in acute promyelocytic leukemia
McClellan, J. S., Kohrt, H. E., Coutre, S., Gotlib, J. R., Majeti, R., Alizadeh, A. A., & Medeiros, B. C. (2012). Treatment advances have not improved the early death rate in acute promyelocytic leukemia. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 97(1), 133–36. -
Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia
Liedtke, M., Twist, C. J., Medeiros, B. C., Gotlib, J. R., Berube, C., Bieber, M. M., … Coutre, S. E. (2012). Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 97(1), 30–37. -
Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia
Pollyea, D. A., Kohrt, H. E., Gallegos, L., Figueroa, M. E., Abdel-Wahab, O., Zhang, B., … Medeiros, B. C. (2012). Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. LEUKEMIA, 26(5), 893–901. -
Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia
Medeiros, B. C., Kohrt, H. E., Gotlib, J., Coutre, S. E., Zhang, B., Arber, D. A., & Zehnder, J. L. (2012). Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia. AMERICAN JOURNAL OF HEMATOLOGY, 87(1), 45–50. -
"It doesn't matter if you're black or white", does it?
Medeiros, B. C. (2012). "It doesn't matter if you're black or white", does it? LEUKEMIA RESEARCH, 36(2), 127–127. -
Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia
Walter, R. B., Medeiros, B. C., Powell, B. L., Schiffer, C. A., Appelbaum, F. R., & Estey, E. H. (2012). Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 97(5), 739–742. -
Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia
Medeiros, B. C., Othus, M., Estey, E. H., Fang, M., & Appelbaum, F. R. (2012). Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 97(9), 1401–4. -
Unveiling the complexity of CK+ AML.
Medeiros, B. C. (2012). Unveiling the complexity of CK+ AML. Blood, 119(9), 1958–59. -
Blood consult: monosomal karyotype acute myeloid leukemia
Garcia, J. S., Medeiros, B. C., & Appelbaum, F. R. (2012). Blood consult: monosomal karyotype acute myeloid leukemia. BLOOD, 119(24), 5659–60. -
Aggressive EBV-associated Lymphoproliferative Disorder: A Prodrome to Diffuse Large B-cell Lymphoma?
Batra, R., Medeiros, B. C., Zehnder, J. L., Warnke, R. A., & Natkunam, Y. (2012). Aggressive EBV-associated Lymphoproliferative Disorder: A Prodrome to Diffuse Large B-cell Lymphoma? APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 20(3), 325–30. -
2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels
Pollyea, D. A., Kohrt, H. E., Zhang, B., Zehnder, J., Schenkein, D., Fantin, V., … Medeiros, B. C. (2013). 2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels. LEUKEMIA & LYMPHOMA, 54(2), 408–10. -
Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia
Sun, D., Elson, P., Liedtke, M., Medeiros, B. C., Earl, M., Alizadeh, A., … Advani, A. S. (2012). Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia. AMERICAN JOURNAL OF HEMATOLOGY, 87(10), 957–60. -
CD19(-)CD45(low/-)CD38(high)/CD138(+) plasma cells enrich for human tumorigenic myeloma cells
Kim, D., Park, C. Y., Medeiros, B. C., & Weissman, I. L. (2012). CD19(-)CD45(low/-)CD38(high)/CD138(+) plasma cells enrich for human tumorigenic myeloma cells. LEUKEMIA, 26(12), 2530–37. -
Novel agents in acute myeloid leukemia
Ungewickell, A., & Medeiros, B. C. (2012). Novel agents in acute myeloid leukemia. INTERNATIONAL JOURNAL OF HEMATOLOGY, 96(2), 178–85. -
CD11b expression and MK+ AML: A sign of impending doom?
Medeiros, B. C. (2013). CD11b expression and MK+ AML: A sign of impending doom? LEUKEMIA RESEARCH, 37(2), 121–121. -
Hemophagocytic lymphohistiocytosis in pregnancy: a case report and review of treatment options
Dunn, T., Cho, M., Medeiros, B., Logan, A., Ungewickell, A., & Liedtke, M. (2012). Hemophagocytic lymphohistiocytosis in pregnancy: a case report and review of treatment options. HEMATOLOGY, 17(6), 325–28. -
Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.
Pollyea, D. A., Zehnder, J., Coutre, S., Gotlib, J. R., Gallegos, L., Abdel-Wahab, O., … Medeiros, B. C. (2013). Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. Haematologica, 98(4), 591–96. -
A single-center experience of the nationwide daunorubicin shortage: substitution with doxorubicin in adult acute lymphoblastic leukemia.
Patel, S., Liedtke, M., Ngo, D., & Medeiros, B. C. (2013). A single-center experience of the nationwide daunorubicin shortage: substitution with doxorubicin in adult acute lymphoblastic leukemia. Leukemia & Lymphoma, 54(10), 2231–35. -
Myelomastocytic Leukemia: A Clinical, Pathologic, and Molecular Genetic Study
McGuire, A., Shier, L. R., Gotlib, J., Medeiros, B., Wong, K., Corless, C., … George, T. I. (2009). Myelomastocytic Leukemia: A Clinical, Pathologic, and Molecular Genetic Study. Presented at the 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, BOSTON,MA: NATURE PUBLISHING GROUP. -
Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study
Dinner, S. N., Dunn, T. J., Medeiros, B. C., Coutre, S. E., Berube, C., Gotlib, J., & Liedtke, M. (2012). Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study. BLOOD, 120(21). -
A Phase I/II Study of Bortezomib (VELCADE) in Combination with Pralatrexate in Relapsed/Refractory Multiple Myeloma
Dunn, T. J., Dinner, S. N., Berube, C., Gotlib, J., Coutre, S. E., Medeiros, B. C., & Liedtke, M. (2012). A Phase I/II Study of Bortezomib (VELCADE) in Combination with Pralatrexate in Relapsed/Refractory Multiple Myeloma. BLOOD, 120(21). -
Temozolomide In Acute Myeloid Leukemia: A MGMT Promoter Methylation Status-Based Treatment Stratification
Medeiros, B. C., Kohrt, H. E., Rajwanshi, R., Gotlib, J., Coutre, S., Liedtke, M., … Zehnder, J. L. (2010). Temozolomide In Acute Myeloid Leukemia: A MGMT Promoter Methylation Status-Based Treatment Stratification. BLOOD, 116(21), 1357–58. -
A Phase I Study of Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia (AML)
Pollyea, D. A., Kohrt, H. E., Gallegos, L., Berube, C., Coutre, S., Gotlib, J., … Medeiros, B. C. (2010). A Phase I Study of Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia (AML). BLOOD, 116(21), 1347–47. -
Early Mortality in Acute Promyelocytic Leukemia May Be Higher Than Previously Reported.
Alizadeh, A. A., McClellan, J. S., Gotlib, J. R., Coutre, S., Majeti, R., Kohrt, H. E., & Medeiros, B. C. (2009). Early Mortality in Acute Promyelocytic Leukemia May Be Higher Than Previously Reported. BLOOD, 114(22), 420–21. -
Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancer
Wang, M., Medeiros, B. C., Erba, H. P., DeAngelo, D. J., Giles, F. J., & Swords, R. T. (2011). Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancer. EXPERT OPINION ON THERAPEUTIC TARGETS, 15(3), 253–64. -
Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) or Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm
Becker, P. S., Medeiros, B. C., Appelbaum, F. R., Scott, B. L., Hendrie, P. C., Storer, B., … Estey, E. H. (2011). Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) or Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm. BLOOD, 118(21), 1545–1545. -
Multicenter Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm
Becker, P. S., Medeiros, B. C., Stein, A. S., Appelbaum, F. R., Scott, B. L., Delaney, C., … Estey, E. H. (2012). Multicenter Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm. BLOOD, 120(21). -
Multiple Myeloma
Anderson, K. C., Alsina, M., Bensinger, W., Biermann, S., Chanan-Khan, A., Cohen, A. D., … Yunus, F. (2009). Multiple Myeloma. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 7(9), 908–42. -
Interim results of protracted low doses of temozolomide in high-risk acute myeloid leukemia
Medeiros, B. C., Gotlib, J. R., Coutre, S. E., Jones, C., Khan, S. A., Rajwanshi, R., … Zehnder, J. (2009). Interim results of protracted low doses of temozolomide in high-risk acute myeloid leukemia. JOURNAL OF CLINICAL ONCOLOGY, 27(15). -
Multiple Myeloma
Anderson, K. C., Alsina, M., Bensinger, W., Biermann, J. S., Chanan-Khan, A., Cohen, A. D., … Yunus, F. (2011). Multiple Myeloma. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 9(10), 1146–83. -
PHASE 2 TRIAL OF VORINOSTAT (SAHA) IN COMBINATION WITH GEMTUZUMAB OZOGAMICIN AS INDUCTION AND POST-REMISSION THERAPY IN OLDER PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA (AML)
Walter, B., Medeiros, B., Nielsen-Stoeck, M., Harrington, E., Powell, B., Schiffer, C., … Estey, E. (2010). PHASE 2 TRIAL OF VORINOSTAT (SAHA) IN COMBINATION WITH GEMTUZUMAB OZOGAMICIN AS INDUCTION AND POST-REMISSION THERAPY IN OLDER PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA (AML). Presented at the 15th Annual Meeting of the European-Hematology-Association, BARCELONA,SPAIN: FERRATA STORTI FOUNDATION. -
Is Time of the Essence in Adult Acute Myeloid Leukemia (AML)? Time to Blast Clearance and Time to Induction Therapy Fail to Predict Overall Survival (OS).
Kohrt, H. E., Patel, S., Ho, M., Owen, T., Majeti, R., Gotlib, J. R., … Alizadeh, A. A. (2009). Is Time of the Essence in Adult Acute Myeloid Leukemia (AML)? Time to Blast Clearance and Time to Induction Therapy Fail to Predict Overall Survival (OS). BLOOD, 114(22), 646–47. -
Plasma cell leukemia: concepts and management
Liedtke, M., & Medeiros, B. C. (2010). Plasma cell leukemia: concepts and management. EXPERT REVIEW OF HEMATOLOGY, 3(5), 539–49. -
New treatment approaches for older adults with multiple myeloma
Wildes, T. M., Vij, R., Petersdorf, S. H., Medeiros, B. C., & Hurria, A. (2012). New treatment approaches for older adults with multiple myeloma. JOURNAL OF GERIATRIC ONCOLOGY, 3(3), 279–90. -
Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2013 Featured Updates to the NCCN Guidelines
Anderson, K. C., Alsina, M., Bensinger, W., Biermann, J. S., Cohen, A. D., Devine, S., … Shead, D. A. (2012). Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2013 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(10), 1211–19. -
Senior Adult Oncology
Hurria, A., Browner, I. S., Cohen, H. J., Denlinger, C. S., deShazo, M., Extermann, M., … Wildes, T. (2012). Senior Adult Oncology. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(2), 162–209. -
Qualitative analysis of practicing oncologists' attitudes and experiences regarding collection of patient-reported outcomes.
Jagsi, R., Chiang, A., Polite, B. N., Medeiros, B. C., McNiff, K., Abernethy, A. P., … Loehrer, P. J. (2013). Qualitative analysis of practicing oncologists' attitudes and experiences regarding collection of patient-reported outcomes. Journal of Oncology Practice / American Society of Clinical Oncology, 9(6), e290–7. -
Unsuccessful diagnostic cytogenetic analysis is a poor prognostic feature in acute myeloid leukaemia
Medeiros, B. C., Othus, M., Estey, E. H., Fang, M., & Appelbaum, F. R. (2014). Unsuccessful diagnostic cytogenetic analysis is a poor prognostic feature in acute myeloid leukaemia. BRITISH JOURNAL OF HAEMATOLOGY, 164(2), 245–50. -
Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission.
Corces-Zimmerman, M. R., Hong, W.-J., Weissman, I. L., Medeiros, B. C., & Majeti, R. (2014). Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proceedings of the National Academy of Sciences of the United States of America, 111(7), 2548–53. -
Hematopoietic Stem Cell Transplantation for Hematologic Malignancies in Older Adults: Geriatric Principles in the Transplant Clinic
Wildes, T. M., Stirewalt, D. L., Medeiros, B., & Hurria, A. (2014). Hematopoietic Stem Cell Transplantation for Hematologic Malignancies in Older Adults: Geriatric Principles in the Transplant Clinic. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 12(1), 128–136. -
Senior adult oncology, version 2.2014: clinical practice guidelines in oncology .
Hurria, A., Wildes, T., Blair, S. L., Browner, I. S., Cohen, H. J., deShazo, M., … Sundar, H. (2014). Senior adult oncology, version 2.2014: clinical practice guidelines in oncology . Journal of the National Comprehensive Cancer Network , 12(1), 82–126. -
Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study
Walter, R. B., Medeiros, B. C., Gardner, K. M., Orlowski, K. F., Gallegos, L., Scott, B. L., … Estey, E. H. (2014). Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study. HAEMATOLOGICA, 99(1), 54–59. -
Facts about FCE (Fludarabine, Cytarabine, Etoposide) in Acute Myeloid Leukemia.
Medeiros, B. C. (2014). Facts about FCE (Fludarabine, Cytarabine, Etoposide) in Acute Myeloid Leukemia. Acta Haematologica, 131(4), 200–201. -
Mcl-1 dependence predicts response to vorinostat and gemtuzumab ozogamicin in acute myeloid leukemia
Pierceall, W. E., Lena, R. J., Medeiros, B. C., Blake, N., Doykan, C., Elashoff, M., … Walter, R. B. (2014). Mcl-1 dependence predicts response to vorinostat and gemtuzumab ozogamicin in acute myeloid leukemia. LEUKEMIA RESEARCH, 38(5), 564–68. -
NCCN clinical practice guidelines in oncology: multiple myeloma.
Anderson, K. C., Alsina, M., Bensinger, W., Biermann, J. S., Chanan-Khan, A., Cohen, A. D., … Yunus, F. (2009). NCCN clinical practice guidelines in oncology: multiple myeloma. Journal of the National Comprehensive Cancer Network , 7(9), 908–942. -
Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013.
Anderson, K. C., Alsina, M., Bensinger, W., Biermann, J. S., Cohen, A. D., Devine, S., … Shead, D. A. (2012). Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013. Journal of the National Comprehensive Cancer Network , 10(10), 1211–1219. -
Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients.
Frankel, A. E., Woo, J. H., Ahn, C., Pemmaraju, N., Medeiros, B. C., Carraway, H. E., … Rowinsky, E. (2014). Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood, 124(3), 385–92. -
Monosomal karyotype acute myeloid leukemia: tread lightly.
Garcia, J. S., & Medeiros, B. C. (2015). Monosomal karyotype acute myeloid leukemia: tread lightly. Acta Haematologica, 133(4), 324–26. -
Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia
Liedtke, M., Dunn, T., Dinner, S., Coutre, S. E., Berubea, C., Gotlib, J., … Medeiros, B. (2014). Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia. LEUKEMIA RESEARCH, 38(12), 1441–45. -
Polypharmacy in AML: the tip of the iceberg.
Patel, S., & Medeiros, B. C. (2014). Polypharmacy in AML: the tip of the iceberg. Leukemia Research, 38(11), 1378–79. -
Increased plasma d-2-hydroxyglutarate in isocitrate dehydrogenase 2-mutated blastic plasmacytoid dendritic cell neoplasm.
Rakheja, D., Fuda, F., Vandergriff, T., Boriack, R., Medeiros, B. C., Frankel, A. E., & Chen, W. (2015). Increased plasma d-2-hydroxyglutarate in isocitrate dehydrogenase 2-mutated blastic plasmacytoid dendritic cell neoplasm. Human Pathology, 46(2), 322–26. -
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.
Chan, S. M., Thomas, D., Corces-Zimmerman, M. R., Xavy, S., Rastogi, S., Hong, W.-J., … Majeti, R. (2015). Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nature Medicine, 21(2), 178–84. -
European LeukemiaNet classification intermediate risk-1 cohort is associated with poor outcomes in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation
Medeiros, B. C., Tian, L., Robenson, S., Laport, G. G., JOHNSTON, L. J., Shizuru, J. A., … Lowsky, R. (2014). European LeukemiaNet classification intermediate risk-1 cohort is associated with poor outcomes in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. BLOOD CANCER JOURNAL, 4. -
Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia.
Medeiros, B. C., Othus, M., Fang, M., Appelbaum, F. R., & Erba, H. P. (2015). Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia. Haematologica, 100(3), 331–35. -
G-CSF Priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm
Becker, P. S., Medeiros, B. C., Stein, A. S., Othus, M., Appelbaum, F. R., Forman, S. J., … Estey, E. H. (2015). G-CSF Priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm. AMERICAN JOURNAL OF HEMATOLOGY, 90(4), 295–300. -
Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study
Swords, R. T., Erba, H. P., DeAngelo, D. J., Bixby, D. L., Altman, J. K., Maris, M., … Medeiros, B. C. (2015). Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study. BRITISH JOURNAL OF HAEMATOLOGY, 169(4), 534–543. -
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia
Chan, S. M., Thomas, D., Corces-Zimmerman, M. R., Xavy, S., Rastogi, S., Hong, W.-J., … Majeti, R. (2015). Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. NATURE MEDICINE, 21(2), 90–96. -
Transfusion-related acute lung injury (TRALI) following platelet transfusion in a patient receiving high-dose Interleukin-2 for treatment of metastatic renal cell carcinoma
Medeiros, B. C., Kogel, K. E., & Kane, M. A. (2003). Transfusion-related acute lung injury (TRALI) following platelet transfusion in a patient receiving high-dose Interleukin-2 for treatment of metastatic renal cell carcinoma. TRANSFUSION AND APHERESIS SCIENCE, 29(1), 25–27. -
Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States
Medeiros, B. C., Satram-Hoang, S., Hurst, D., Hoang, K. Q., Momin, F., & Reyes, C. (2015). Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States. ANNALS OF HEMATOLOGY, 94(7), 1127–38. -
Improvements in the early death rate among 9380 patients with acute myeloid leukemia after initial therapy: A SEER database analysis
Percival, M.-E. M., Tao, L., Medeiros, B. C., & Clarke, C. A. (2015). Improvements in the early death rate among 9380 patients with acute myeloid leukemia after initial therapy: A SEER database analysis. CANCER, 121(12), 2004–12. -
Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia.
Liedtke, M., Dunn, T., Dinner, S., Coutré, S. E., Berube, C., Gotlib, J., … Medeiros, B. (2014). Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia. Leukemia Research, 38(12), 1441–45. -
Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia.
Khalife, J., Radomska, H. S., Santhanam, R., Huang, X., Neviani, P., Saultz, J., … Marcucci, G. (2015). Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia. Leukemia. -
Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile.
Percival, M.-E. M., Medeiros, B. C., Tian, L., Robeson, S., Laport, G. G., Johnston, L. J., … Lowsky, R. (2015). Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile. Bone Marrow Transplantation. -
Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia.
Khodadoust, M. S., Luo, B., Medeiros, B. C., Johnson, R. C., Ewalt, M. D., Schalkwyk, A. S., … Gotlib, J. (2016). Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia. Leukemia, 30(4), 947–50. -
Disparities in early death and survival in children, adolescents and young adults with acute promyelocytic leukemia in California.
Abrahão, R., Ribeiro, R. C., Medeiros, B. C., Keogh, R. H., & Keegan, T. H. (2015). Disparities in early death and survival in children, adolescents and young adults with acute promyelocytic leukemia in California. Cancer. -
Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy.
Behbehani, G. K., Samusik, N., Bjornson, Z. B., Fantl, W. J., Medeiros, B. C., & Nolan, G. P. (2015). Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy. Cancer Discovery, 5(9), 988–1003. -
Chemotherapy dose in obese AML patients: To cap or not to cap?
Percival, M.-E. M., & Medeiros, B. C. (2015). Chemotherapy dose in obese AML patients: To cap or not to cap? LEUKEMIA RESEARCH, 39(1), 30–32. -
Management considerations in older patients with AML: a 2014 perspective.
Medeiros, B. C. (2014). Management considerations in older patients with AML: a 2014 perspective. [Rinsho Ketsueki] The Japanese Journal of Clinical Hematology, 55(10), 1803–7. -
Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study.
Granfeldt Østgård, L. S., Medeiros, B. C., Sengeløv, H., Nørgaard, M., Andersen, M. K., Dufva, I. H., … Nørgaard, J. M. (2015). Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. -
Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies.
Pasquini, M. C., Zhang, M.-J., Medeiros, B. C., Armand, P., Hu, Z.-H., Nishihori, T., … Weisdorf, D. J. (2016). Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. Biology of Blood and Marrow Transplantation , 22(2), 248–57. -
Chemotherapy options for previously untreated acute myeloid leukemia
Lynch, R. C., & Medeiros, B. C. (2015). Chemotherapy options for previously untreated acute myeloid leukemia. EXPERT OPINION ON PHARMACOTHERAPY, 16(14), 2149–62. -
Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome.
Narayan, R., Garcia, J. S., Percival, M.-E. M., Berube, C., Coutre, S., Gotlib, J., … Medeiros, B. C. (2016). Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome. Leukemia & Lymphoma, 57(3), 609–15. -
Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignancies
Lewinsohn, M., Brown, A. L., Weinel, L. M., Phung, C., Rafidi, G., Lee, M. K., … Scott, H. S. (2016). Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignancies. BLOOD, 127(8), 1017–23. -
Predictors of early death and survival among children, adolescents and young adults with acute myeloid leukaemia in California, 1988-2011: a population-based study.
Abrahão, R., Keogh, R. H., Lichtensztajn, D. Y., Marcos-Gragera, R., Medeiros, B. C., Coleman, M. P., … Keegan, T. H. (2016). Predictors of early death and survival among children, adolescents and young adults with acute myeloid leukaemia in California, 1988-2011: a population-based study. British Journal of Haematology. -
A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma.
Dunn, T. J., Dinner, S., Price, E., Coutré, S. E., Gotlib, J., Hao, Y., … Liedtke, M. (2016). A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma. British Journal of Haematology, 173(2), 253–59. -
Individualizing Therapeutic Strategies in Acute Myeloid Leukemia: Moving Beyond the 'One-Size-Fits-All' Approach.
Jonas, B. A., & Medeiros, B. C. (2016). Individualizing Therapeutic Strategies in Acute Myeloid Leukemia: Moving Beyond the 'One-Size-Fits-All' Approach. Oncology (Williston Park, N.Y.), 30(4). -
Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome
Narayan, R., Garcia, J. S., Percival, M.-E. M., Berube, C., Coutre, S., Gotlib, J., … Medeiros, B. C. (2016). Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome. LEUKEMIA & LYMPHOMA, 57(3), 609–15. -
Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (> 5 years)
Medeiros, B. C., Minden, M. D., Schuh, A. C., Schimmer, A. D., Yee, K., Lipton, J. H., … Brandwein, J. M. (2007). Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (> 5 years). LEUKEMIA & LYMPHOMA, 48(1), 65–71. -
Inv (11)(p15q21) in donor-derived Ph-negative cells in a patient with chronic myeloid leukemia in relapse successfully treated with imatinib mesylate post allogeneic stem cell transplantation
Medeiros, B. C., Chun, K., Kamel-Reid, S., & Lipton, J. (2007). Inv (11)(p15q21) in donor-derived Ph-negative cells in a patient with chronic myeloid leukemia in relapse successfully treated with imatinib mesylate post allogeneic stem cell transplantation. AMERICAN JOURNAL OF HEMATOLOGY, 82(8), 758–760. -
Absence of FTL3 mutations in patients with JAK2(V617F) mutation negative essential thrombocythemia
Medeiros, B. C., Zhang, T., Lipton, J. H., & Kamel-Reid, S. (2007). Absence of FTL3 mutations in patients with JAK2(V617F) mutation negative essential thrombocythemia. AMERICAN JOURNAL OF HEMATOLOGY, 82(4), 293–294. -
Management of invasive Aspergillosis in acute myelogenous leukemia.
Medeiros, B. C. (2016). Management of invasive Aspergillosis in acute myelogenous leukemia. Clinical Advances in Hematology & Oncology : H&O, 14(7), 502–4. -
Identification of Doxorubicin as an Inhibitor of the IRE1a-XBP1 Axis of the Unfolded Protein Response.
Jiang, D., Lynch, C., Medeiros, B. C., Liedtke, M., Bam, R., Tam, A. B., … Koong, A. C. (2016). Identification of Doxorubicin as an Inhibitor of the IRE1a-XBP1 Axis of the Unfolded Protein Response. Scientific Reports, 6, 33353-? -
Isocitrate dehydrogenase mutations in myeloid malignancies.
Medeiros, B. C., Fathi, A. T., Dinardo, C. D., Pollyea, D. A., Chan, S. M., & SWORDS, R. (2016). Isocitrate dehydrogenase mutations in myeloid malignancies. Leukemia. -
Improved outcome in acute myeloid leukemia patients enrolled in clinical trials: A national population-based cohort study of Danish intensive chemotherapy patients.
Østgård, L. S., Nørgaard, M., Sengeløv, H., Medeiros, B. C., Kjeldsen, L., Overgaard, U. M., … Nørgaard, J. M. (2016). Improved outcome in acute myeloid leukemia patients enrolled in clinical trials: A national population-based cohort study of Danish intensive chemotherapy patients. Oncotarget. -
Autophagy mediates proteolysis of NPM1 and HEXIM1 and sensitivity to BET inhibition in AML cells.
Huang, M., Garcia, J. S., Thomas, D., Zhu, L., Nguyen, L. X. T., Chan, S. M., … Mitchell, B. S. (2016). Autophagy mediates proteolysis of NPM1 and HEXIM1 and sensitivity to BET inhibition in AML cells. Oncotarget. -
Why do subjects on clinical trials discontinue therapy? Do we really know?
Medeiros, B. C., & Gale, R. P. (2016). Why do subjects on clinical trials discontinue therapy? Do we really know? Leukemia Research, 51, 19–21. -
NCCN Guidelines Insights: Older Adult Oncology, Version 2.2016.
VanderWalde, N., Jagsi, R., Dotan, E., Baumgartner, J., Browner, I. S., Burhenn, P., … Hurria, A. (2016). NCCN Guidelines Insights: Older Adult Oncology, Version 2.2016. Journal of the National Comprehensive Cancer Network , 14(11), 1357–70. -
Senior Adult Oncology, Version 2.2014
Hurria, A., Wildes, T., Blair, S. L., Browner, I. S., Cohen, H. J., deShazo, M., … Sundar, H. (2014). Senior Adult Oncology, Version 2.2014. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 12(1), 82–126. -
NCCN Guidelines (R) Insights Older Adult Oncology, Version 2.2016 Featured Updates to the NCCN Guidelines
VanderWalde, N., Jagsi, R., Dotan, E., Baumgartner, J., Browner, I. S., Burhenn, P., … Hurria, A. (2016). NCCN Guidelines (R) Insights Older Adult Oncology, Version 2.2016 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 14(11), 1357–70. -
A study of disseminated intravascular coagulation in acute leukemia reveals markedly elevated D-dimer levels are a sensitive indicator of acute promyelocytic leukemia.
Shahmarvand, N., Oak, J. S., Cascio, M. J., Alcasid, M., Goodman, E., Medeiros, B. C., … Ohgami, R. S. (2017). A study of disseminated intravascular coagulation in acute leukemia reveals markedly elevated D-dimer levels are a sensitive indicator of acute promyelocytic leukemia. International Journal of Laboratory Hematology. -
Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia
Carey, A., Edwards, D. K., Eide, C. A., Newell, L., Traer, E., Medeiros, B. C., … Agarwal, A. (2017). Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia. CELL REPORTS, 18(13), 3204–18. -
Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes.
Swords, R. T., Watts, J., Erba, H. P., Altman, J. K., Maris, M., ANWER, F., … DeAngelo, D. J. (2017). Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes. Blood Cancer Journal, 7(2). -
Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes.
Swords, R. T., Watts, J., Erba, H. P., Altman, J. K., Maris, M., ANWER, F., … DeAngelo, D. J. (2017). Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes. Blood Cancer Journal, 7(2). -
Novel Therapeutics in Acute Myeloid Leukemia.
DiNardo, C. D., Stone, R. M., & Medeiros, B. C. (2017). Novel Therapeutics in Acute Myeloid Leukemia. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Meeting, 37, 495–503. -
relapsed or refractory acute myeloid leukemia.
Stein, E. M., DiNardo, C. D., Pollyea, D. A., Fathi, A. T., Roboz, G. J., Altman, J. K., … Tallman, M. S. (2017). relapsed or refractory acute myeloid leukemia. Blood. -
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.
Stone, R. M., Mandrekar, S. J., Sanford, B. L., Laumann, K., Geyer, S., Bloomfield, C. D., … Döhner, H. (2017). Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. The New England Journal of Medicine. -
Unpaired extracellular cysteine mutations of CSF3R mediate gain or loss of function.
Zhang, H., Means, S., Schultz, A. R., Watanabe-Smith, K., Medeiros, B. C., Bottomly, D., … Tyner, J. W. (2017). Unpaired extracellular cysteine mutations of CSF3R mediate gain or loss of function. Cancer Research. -
Isocitrate dehydrogenase mutations in myeloid malignancies
Medeiros, B. C., Fathi, A. T., Dinardo, C. D., Pollyea, D. A., Chan, S. M., & SWORDS, R. (2017). Isocitrate dehydrogenase mutations in myeloid malignancies. LEUKEMIA, 31(2), 272–81. -
Localized skin-limited blastic plasmacytoid dendritic cell neoplasm: A subset with possible durable remission without transplantation.
Amitay-Laish, I., Sundram, U., Hoppe, R. T., Hodak, E., Medeiros, B. C., & Kim, Y. H. (2017). Localized skin-limited blastic plasmacytoid dendritic cell neoplasm: A subset with possible durable remission without transplantation. JAAD Case Reports, 3(4), 310–15. -
Long non-coding RNAs: another brick in the wall of normal karyotype acute myeloid leukemia?
Medeiros, B. C. (2017). Long non-coding RNAs: another brick in the wall of normal karyotype acute myeloid leukemia? Haematologica, 102(8), 1301–3. -
Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.
Kurtz, S. E., Eide, C. A., Kaempf, A., Khanna, V., Savage, S. L., Rofelty, A., … Tyner, J. W. (2017). Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies. Proceedings of the National Academy of Sciences of the United States of America. -
Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality.
Sorror, M. L., Storer, B. E., Fathi, A. T., Gerds, A. T., Medeiros, B. C., Shami, P., … Estey, E. H. (2017). Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality. JAMA Oncology. -
Effects of Education and Income on Treatment and Outcome in Patients With Acute Myeloid Leukemia in a Tax-Supported Health Care System: A National Population-Based Cohort Study.
Østgård, L. S., Nørgaard, M., Medeiros, B. C., Friis, L. S., Schoellkopf, C., Severinsen, M. T., … Nørgaard, J. M. (2017). Effects of Education and Income on Treatment and Outcome in Patients With Acute Myeloid Leukemia in a Tax-Supported Health Care System: A National Population-Based Cohort Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2017736728. -
Impact of Allogeneic Stem Cell Transplantation in First Complete Remission in Acute Myeloid Leukemia: a National Population-Based Cohort Study.
Østgård, L. S., Lund, J. L., Nørgaard, J. M., Nørgaard, M., Medeiros, B. C., Nielsen, B., … Sengeløv, H. (2017). Impact of Allogeneic Stem Cell Transplantation in First Complete Remission in Acute Myeloid Leukemia: a National Population-Based Cohort Study. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation. -
Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide or azacitidine in persons =65 years with newly-diagnosed acute myeloid leukemia.
Medeiros, B. C., McCaul, K., Kambhampati, S., Pollyea, D. A., Kumar, R., Silverman, L. R., … Gale, R. P. (2017). Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide or azacitidine in persons =65 years with newly-diagnosed acute myeloid leukemia. Haematologica. -
Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.
DeAngelo, D. J., George, T. I., Linder, A., Langford, C., Perkins, C., Ma, J., … Gotlib, J. (2017). Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. Leukemia. -
Mutations in UBA3 Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924 in Human Leukemic Cells
Xu, G. W., Toth, J. I., da Silva, S. R., Paiva, S.-L., Lukkarila, J. L., Hurren, R., … Schimmer, A. D. (2014). Mutations in UBA3 Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924 in Human Leukemic Cells. PLOS ONE, 9(4). -
Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm.
Walter, R. B., Othus, M., Orlowski, K. F., McDaniel, E. N., Scott, B. L., Becker, P. S., … Estey, E. H. (2017). Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm. Haematologica. -
Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML).
Advani, A. S., Li, H., Michaelis, L. C., Medeiros, B. C., Liedtke, M., List, A. F., … Appelbaum, F. R. (2018). Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML). Leukemia Research, 67, 17–20. -
Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing.
Medeiros, B. C., Possick, J., & Fradley, M. (2018). Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing. Blood Reviews. -
Autoimmune diseases, infections, use of antibiotics and the risk of acute myeloid leukaemia: a national population-based case-control study.
Østgård, L. S., Nørgaard, M., Pedersen, L., Østgård, R. D., Medeiros, B. C., Overgaard, U. M., … Jensen, M. K. (2018). Autoimmune diseases, infections, use of antibiotics and the risk of acute myeloid leukaemia: a national population-based case-control study. British Journal of Haematology. -
Interpretation of clinical endpoints in trials of acute myeloid leukemia.
Medeiros, B. C. (2018). Interpretation of clinical endpoints in trials of acute myeloid leukemia. Leukemia Research, 68, 32–39. -
A Phase I/II Trial of the Combination of Azacitidine and Gemtuzumab Ozogamicin for Treatment of Relapsed Acute Myeloid Leukemia.
Medeiros, B. C., Tanaka, T. N., Balaian, L., Bashey, A., Guzdar, A., Li, H., … Ball, E. D. (2018). A Phase I/II Trial of the Combination of Azacitidine and Gemtuzumab Ozogamicin for Treatment of Relapsed Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma & Leukemia. -
The PI3K Inhibitor GDC-0941 Induces Growth Arrest and Apoptosis of Acute Myeloid Leukemia Cells
Sun, L., Berry, L., Du, C., Ma, X. M., Shi, L., Medeiros, B. C., & Ebens, A. J. (2009). The PI3K Inhibitor GDC-0941 Induces Growth Arrest and Apoptosis of Acute Myeloid Leukemia Cells. BLOOD, 114(22), 1456. -
AG-221, an Oral, Selective, First-in-Class, Potent Inhibitor of the IDH2 Mutant Metabolic Enzyme, Induces Durable Remissions in a Phase I Study in Patients with IDH2 Mutation Positive Advanced Hematologic Malignancies
Stein, E. M., Altman, J. K., Collins, R., DeAngelo, D. J., Fathi, A. T., Flinn, I., … de Botton, S. (2014). AG-221, an Oral, Selective, First-in-Class, Potent Inhibitor of the IDH2 Mutant Metabolic Enzyme, Induces Durable Remissions in a Phase I Study in Patients with IDH2 Mutation Positive Advanced Hematologic Malignancies. BLOOD. AMER SOC HEMATOLOGY. -
Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study
Dinner, S. N., Dunn, T. J., Medeiros, B. C., Coutre, S. E., Berube, C., Gotlib, J., & Liedtke, M. (2012). Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study. BLOOD. AMER SOC HEMATOLOGY. -
Azacitidine Plus Lenalidomide for Untreated AML Patients Ineligible for Conventional Chemotherapy
Pollyea, D. A., Zehnder, J. L., Coutre, S., Gotlib, J., Gallegos, L., Greenberg, P., … Medeiros, B. C. (2012). Azacitidine Plus Lenalidomide for Untreated AML Patients Ineligible for Conventional Chemotherapy. BLOOD. AMER SOC HEMATOLOGY. -
Absolute Lymphocyte Count At Day 28 Independently Predicts Event-Free and Overall Survival in Adults with Newly Diagnosed Acute Lymphocytic Leukemia
Sun, D., Elson, P., Liedtke, M., Medeiros, B. C., Earl, M., Alizadeh, A. A., … Advani, A. S. (2011). Absolute Lymphocyte Count At Day 28 Independently Predicts Event-Free and Overall Survival in Adults with Newly Diagnosed Acute Lymphocytic Leukemia. BLOOD, 118(21), 1095. -
A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.
Dinner, S., Dunn, T. J., Price, E., Coutré, S. E., Gotlib, J., Berube, C., … Liedtke, M. (2018). A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma. International Journal of Hematology. -
Impact of Comorbidities at Diagnosis of Acute Myeloid Leukemia on One-Year Mortality
Sorror, M. L., Storer, B. E., Elsawy, M., Fathi, A. T., Brunner, A., Gerds, A. T., … Estey, E. H. (2015). Impact of Comorbidities at Diagnosis of Acute Myeloid Leukemia on One-Year Mortality. BLOOD. AMER SOC HEMATOLOGY. -
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.
Lancet, J. E., Uy, G. L., Cortes, J. E., Newell, L. F., Lin, T. L., Ritchie, E. K., … Medeiros, B. C. (2018). CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2017776112. -
Non-zero-sum game of transfusions: EOL in leukemia
Medeiros, B. C. (2018). Non-zero-sum game of transfusions: EOL in leukemia. BLOOD, 132(7), 676-+. -
Real-World Treatment Patterns and Outcomes among Elderly Acute Myeloid Leukemia Patients in the United States
Satram-Hoang, S., Reyes, C., Hurst, D., Hoang, K. Q., & Medeiros, B. C. (2016). Real-World Treatment Patterns and Outcomes among Elderly Acute Myeloid Leukemia Patients in the United States. BIG DATA ON REAL-WORLD APPLICATIONS, 23–40. -
Associations between cohabitation status, treatment, and outcome in AML patients: a national population-based study
Ostgard, L. S. G., Norgaard, M., Medeiros, B. C., Severinsen, M. T., Friis, L. S., Marcher, C. W., … Norgaard, J. M. (2018). Associations between cohabitation status, treatment, and outcome in AML patients: a national population-based study. BLOOD, 131(24), 2730–33. -
National Survey of Pathologists on the Application of Ancillary Testing in the Diagnosis of Acute Myeloid Leukemia
Hasserjian, R., Altman, J., Denzen, E., Block, A. M., Klepin, H., Medeiros, B., … Burns, L. (2018). National Survey of Pathologists on the Application of Ancillary Testing in the Diagnosis of Acute Myeloid Leukemia. MODERN PATHOLOGY, 31, 520. -
Subanalysis of Patients with Secondary Acute Myeloid Leukemia (sAML) with Refractory Anemia with Excess of Blasts in Transformation (RAEB-T) Enrolled in a Phase 3 Study of CPX-351 Versus Conventional 7+3 Cytarabine and Daunorubicin
Lin, T. L., Uy, G. L., Wieduwilt, M. J., Newell, L. F., Stuart, R. K., Medeiros, B. C., … Lancet, J. E. (2018). Subanalysis of Patients with Secondary Acute Myeloid Leukemia (sAML) with Refractory Anemia with Excess of Blasts in Transformation (RAEB-T) Enrolled in a Phase 3 Study of CPX-351 Versus Conventional 7+3 Cytarabine and Daunorubicin. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 24(3), S228–S229. -
A Study of Disseminated Intravascular Coagulation in Acute Leukemia Reveals Markedly Elevated D-Dimer Levels Are a Sensitive Indicator of Acute Promyelocytic Leukemia
Oak, J., Shahmarvand, N., Alcasid, M., Cascio, M., Goodman, E., Medeiros, B., … Ohgami, R. (2017). A Study of Disseminated Intravascular Coagulation in Acute Leukemia Reveals Markedly Elevated D-Dimer Levels Are a Sensitive Indicator of Acute Promyelocytic Leukemia. MODERN PATHOLOGY, 30, 367A. -
A Study of Disseminated Intravascular Coagulation in Acute Leukemia Reveals Markedly Elevated D-Dimer Levels Are a Sensitive Indicator of Acute Promyelocytic Leukemia
Oak, J., Shahmarvand, N., Alcasid, M., Cascio, M., Goodman, E., Medeiros, B., … Ohgami, R. (2017). A Study of Disseminated Intravascular Coagulation in Acute Leukemia Reveals Markedly Elevated D-Dimer Levels Are a Sensitive Indicator of Acute Promyelocytic Leukemia. LABORATORY INVESTIGATION, 97, 367A. -
Feasibility of Allogeneic Hematopoietic Cell Transplantation Among High-Risk AML Patients in First Complete Remission: Results of the Transplant Objective from the SWOG (S1203) Randomized Phase III Study of Induction Therapy Using Standard 7+3 Therapy or Idarubicin with High-Dose Cytarabine (IA) Versus IA Plus Vorinostat
Pagel, J. M., Othus, M., Garcia-Manero, G., Fang, M., Radich, J. P., Rizzieri, D. A., … Appelbaum, F. R. (2016). Feasibility of Allogeneic Hematopoietic Cell Transplantation Among High-Risk AML Patients in First Complete Remission: Results of the Transplant Objective from the SWOG (S1203) Randomized Phase III Study of Induction Therapy Using Standard 7+3 Therapy or Idarubicin with High-Dose Cytarabine (IA) Versus IA Plus Vorinostat. BLOOD, 128(22). -
Analysis of Efficacy By Age for Patients Aged 60-75 with Untreated Secondary Acute Myeloid Leukemia (AML) Treated with CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial
Medeiros, B. C., Lancet, J. E., Cortes, J. E., Newell, L. F., Lin, T. L., Ritchie, E. K., … Uy, G. L. (2016). Analysis of Efficacy By Age for Patients Aged 60-75 with Untreated Secondary Acute Myeloid Leukemia (AML) Treated with CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial. BLOOD, 128(22). -
SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA plus V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)
Garcia-Manero, G., Othus, M., Pagel, J. M., Radich, J. P., Fang, M., Rizzieri, D. A., … Erba, H. P. (2016). SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA plus V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML). BLOOD, 128(22). -
Survival Following Allogeneic Hematopoietic Cell Transplantation in Older High-Risk Acute Myeloid Leukemia Patients Initially Treated with CPX-351 Liposome Injection Versus Standard Cytarabine and Daunorubicin: Subgroup Analysis of a Large Phase III Trial
Lancet, J. E., Hoering, A., Uy, G. L., Cortes, J. E., Newell, L. F., Lin, T. L., … Medeiros, B. C. (2016). Survival Following Allogeneic Hematopoietic Cell Transplantation in Older High-Risk Acute Myeloid Leukemia Patients Initially Treated with CPX-351 Liposome Injection Versus Standard Cytarabine and Daunorubicin: Subgroup Analysis of a Large Phase III Trial. BLOOD, 128(22). -
A Phase 2 Study of Pracinostat and Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Not Eligible for Induction Chemotherapy: Response and Long-Term Survival Benefit
Manero, G. G., Atallah, E., Khaled, S. K., Arellano, M., Patnaik, M. M., Odenike, O., … Medeiros, B. C. (2016). A Phase 2 Study of Pracinostat and Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Not Eligible for Induction Chemotherapy: Response and Long-Term Survival Benefit. BLOOD, 128(22). -
Intensive Versus Non-Intensive Induction Therapy for Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Two Different Novel Prognostic Models
Sorror, M. L., Storer, B. E., Elsawy, M., Fathi, A. T., Brunner, A. M., Gerds, A. T., … Estey, E. H. (2016). Intensive Versus Non-Intensive Induction Therapy for Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Two Different Novel Prognostic Models. BLOOD. AMER SOC HEMATOLOGY. -
Baseline status of O (6)-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and effect of protracted doses of temozolomide on MGMT in acute leukemia.
Medeiros, B., Khan, S., Rajwanshi, R., Jones, C., & Zehnder, J. (2009). Baseline status of O (6)-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and effect of protracted doses of temozolomide on MGMT in acute leukemia. CANCER RESEARCH, 69. -
CD38(hi)CD138(+) bone marrow cells from multiple myeloma patients engraft into human bone microenvironments in humanized mice.
Kim, D., Medeiros, B., & Weissman, I. (2009). CD38(hi)CD138(+) bone marrow cells from multiple myeloma patients engraft into human bone microenvironments in humanized mice. CANCER RESEARCH, 69. -
Predictors of Early Death and Survival Among Children, Adolescents and Young Adults with Acute Myeloid Leukemia in California, 1988-2011: A Population-Based Study
Abrahao, R., Keogh, R. H., Lichtensztajn, D. Y., Marcos-Gragera, R., Medeiros, B. C., Coleman, M. I., … Keegan, T. H. M. (2015). Predictors of Early Death and Survival Among Children, Adolescents and Young Adults with Acute Myeloid Leukemia in California, 1988-2011: A Population-Based Study. BLOOD, 126(23). -
Final Results from a Phase 2 Study of Pracinostat in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML)
Garcia-Manero, G., Atallah, E., Khaled, S. K., Arellano, M., Patnaik, M. M., Butler, T. A., … Medeiros, B. C. (2015). Final Results from a Phase 2 Study of Pracinostat in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML). BLOOD, 126(23). -
Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial
Stein, E. M., DiNardo, C., Altman, J. K., Collins, R., DeAngelo, D. J., Kantarjian, H. M., … De Botton, S. (2015). Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial. BLOOD. AMER SOC HEMATOLOGY. -
The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with FLT3 Mutations (muts): An International Prospective Randomized (rand) P-Controlled Double-Blind Trial (CALGB 10603/RATIFY [Alliance])
Stone, R. M., Mandrekar, S., Sanford, B. L., Geyer, S., Bloomfield, C. D., Dohner, K., … Dohner, H. (2015). The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with FLT3 Mutations (muts): An International Prospective Randomized (rand) P-Controlled Double-Blind Trial (CALGB 10603/RATIFY [Alliance]). BLOOD, 126(23). -
A Phase 1b Study of Panobinostat in Combination with Idarubicin and Ara-C in Patients with High-Risk Acute Myeloid Leukemia
DeAngelo, D. J., Walker, A. R., Schlenk, R. F., Sierra, J., Medeiros, B. C., Ocio, E. M., … Stuart, R. K. (2015). A Phase 1b Study of Panobinostat in Combination with Idarubicin and Ara-C in Patients with High-Risk Acute Myeloid Leukemia. BLOOD, 126(23). -
Consolidation therapy in acute myeloid leukemia
Behbehani, G. K., & Medeiros, B. C. (2014). Consolidation therapy in acute myeloid leukemia. CANCER CONSULT: EXPERTISE FOR CLINICAL PRACTICE, 67–70. -
Preclinical Activity of a New Proteasome Inhibitor, MLN9708, in Acute Myelogenous Leukemias Expressing NPM1 Mutated Protein
Garcia, J. S., Huang, M., Medeiros, B. C., & Mitchell, B. S. (2014). Preclinical Activity of a New Proteasome Inhibitor, MLN9708, in Acute Myelogenous Leukemias Expressing NPM1 Mutated Protein. BLOOD. AMER SOC HEMATOLOGY. -
Real-World Outcomes Among Elderly Acute Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Medeiros, B. C., Satram-Hoang, S., Hoang, K. Q., Momin, F., Hurst, D., & Reyes, C. (2014). Real-World Outcomes Among Elderly Acute Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. BLOOD, 124(21). -
Comparative Effectiveness of Chemotherapy in an Elderly Acute Myeloid Leukemia Population in the United States
Medeiros, B. C., Satram-Hoang, S., Hoang, K. Q., Momin, F., Hurst, D., & Reyes, C. (2014). Comparative Effectiveness of Chemotherapy in an Elderly Acute Myeloid Leukemia Population in the United States. BLOOD, 124(21). -
Pracinostat in Combination with Azacitidine Produces a High Rate and Rapid Onset of Disease Remission in Patients with Previously Untreated Acute Myeloid Leukemia (AML)
Garcia-Manero, G., Atallah, E., Odenike, O., Medeiros, B. C., Cortes, J. E., Esquibel, V., … Khaled, S. K. (2014). Pracinostat in Combination with Azacitidine Produces a High Rate and Rapid Onset of Disease Remission in Patients with Previously Untreated Acute Myeloid Leukemia (AML). BLOOD, 124(21). -
Pevonedistat (MLN4924), an Investigational, First-in-Class NAE Inhibitor, in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Considered Unfit for Conventional Chemotherapy: Updated Results from the Phase 1 C15009 Trial
Swords, R. T., Savona, M. R., Maris, M. B., Erba, H. P., Berdeja, J. G., Foran, J. M., … Medeiros, B. C. (2014). Pevonedistat (MLN4924), an Investigational, First-in-Class NAE Inhibitor, in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Considered Unfit for Conventional Chemotherapy: Updated Results from the Phase 1 C15009 Trial. BLOOD, 124(21). -
Mass Cytometric Analysis of AML Stem and Early Progenitor Cells Reveals Karyotype and Genotype-Specific Immunophenotypes That May Represent Targets for Antibody-Directed Therapies
Behbehani, G. K., Fantl, W. J., Medeiros, B. C., & Nolan, G. P. (2014). Mass Cytometric Analysis of AML Stem and Early Progenitor Cells Reveals Karyotype and Genotype-Specific Immunophenotypes That May Represent Targets for Antibody-Directed Therapies. BLOOD, 124(21). -
Mass Cytometric Analysis of AML Stem and Early Progenitor Cells Reveals Karyotype and Genotype-Specific Cell Cycle Properties That Correlate with Known Responses to Chemotherapy
Behbehani, G. K., Fantl, W. J., Medeiros, B. C., & Nolan, G. P. (2014). Mass Cytometric Analysis of AML Stem and Early Progenitor Cells Reveals Karyotype and Genotype-Specific Cell Cycle Properties That Correlate with Known Responses to Chemotherapy. BLOOD, 124(21). -
Improvements in the Early Death Rate in Younger Acute Myeloid Leukemia Patients Following Initial Therapy: A SEER Database Analysis
Percival, M.-E. M., Tao, L., Medeiros, B. C., & Clarke, C. A. (2014). Improvements in the Early Death Rate in Younger Acute Myeloid Leukemia Patients Following Initial Therapy: A SEER Database Analysis. BLOOD, 124(21). -
Big Data Analysis of Treatment Patterns and Outcomes Among Elderly Medicare Acute Myeloid Leukemia Patients
Satram-Hoang, S., Reyes, C., Hoang, K. Q., Momin, F., Hurst, D., & Medeiros, B. C. (2014). Big Data Analysis of Treatment Patterns and Outcomes Among Elderly Medicare Acute Myeloid Leukemia Patients. BLOOD, 124(21). -
Isocitrate Dehydrogenase Mutations Induce BCL-2 Dependence in Acute Myeloid Leukemia through Inhibition of Cytochrome C Oxidase Function
Chan, S. M., Thomas, D., Medeiros, B. C., & Majeti, R. (2014). Isocitrate Dehydrogenase Mutations Induce BCL-2 Dependence in Acute Myeloid Leukemia through Inhibition of Cytochrome C Oxidase Function. BLOOD, 124(21). -
Mutations in UBA3 Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924 in Human Leukemic Cells (vol 9, e93530, 2014)
Xu, G. W., Toth, J., da Silva, S. R., Paiva, S.-L., Lukkarila, J. L., & Medeiros, B. (2014). Mutations in UBA3 Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924 in Human Leukemic Cells (vol 9, e93530, 2014). PLOS ONE, 9(10). -
Qualitative analysis of practicing oncologists' attitudes and experiences regarding HIT-facilitated collection of patientreported outcomes
Jagsi, R., Chiang, A. C., Medeiros, B. C., Polite, B. N., McNiff, K., Zon, R., & Loehrer, P. J. (2012). Qualitative analysis of practicing oncologists' attitudes and experiences regarding HIT-facilitated collection of patientreported outcomes. JOURNAL OF CLINICAL ONCOLOGY, 30(34). -
2-Hydroxyglutarate in IDH mutant AML: Predicting Patient Responses, Minimal Residual Disease and Correlations with Methylcytosine and Hydroxymethylcytosine Levels
Pollyea, D. A., Kohrt, H. E., Zhang, B., Zehnder, J. L., Schenkein, D. P., Fantin, V., … Medeiros, B. C. (2011). 2-Hydroxyglutarate in IDH mutant AML: Predicting Patient Responses, Minimal Residual Disease and Correlations with Methylcytosine and Hydroxymethylcytosine Levels. BLOOD. AMER SOC HEMATOLOGY. -
Gemtuzumab Ozogamicin in Combination with Vorinostat and Azacitidine As Induction and Post-Remission Therapy in Older Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML): A Phase 1 Study
Walter, R. B., Medeiros, B. C., Gardner, K. M., & Estey, E. H. (2011). Gemtuzumab Ozogamicin in Combination with Vorinostat and Azacitidine As Induction and Post-Remission Therapy in Older Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML): A Phase 1 Study. BLOOD, 118(21), 670. -
Personalized medicine for acute myelogenous leukemia-At the entrance gate
Swords, R. T., Dezube, B. J., & Medeiros, B. C. (2011). Personalized medicine for acute myelogenous leukemia-At the entrance gate. AMERICAN JOURNAL OF HEMATOLOGY, 86(8), 631–32. -
Influence of Residual Normal Metaphases In Patients with Monosomal Karyotype.
Xie, B., Othus, M., Medeiros, B. C., Fang, M., Appelbaum, F. R., & Estey, E. H. (2010). Influence of Residual Normal Metaphases In Patients with Monosomal Karyotype. BLOOD, 116(21), 701. -
The Novel, Investigational NEDD8-Activating Enzyme Inhibitor MLN4924 In Adult Patients with Acute Myeloid Leukemia (AML) or High-Grade Myelodysplastic Syndromes (MDS): A Phase 1 Study
Swords, R. T., Erba, H. P., DeAngelo, D. J., Smith, P. G., Pickard, M. D., Dezube, B. J., … Medeiros, B. C. (2010). The Novel, Investigational NEDD8-Activating Enzyme Inhibitor MLN4924 In Adult Patients with Acute Myeloid Leukemia (AML) or High-Grade Myelodysplastic Syndromes (MDS): A Phase 1 Study. BLOOD, 116(21), 288. -
Cytarabine Dose for Acute Myeloid Leukemia
Mori, J., Tsubokura, M., & Kami, M. (2011). Cytarabine Dose for Acute Myeloid Leukemia. NEW ENGLAND JOURNAL OF MEDICINE, 364(22), 2166–67. -
Update of a Phase I/II Trial of 5-Azacytidine Prior to Gemtuzumab Ozogamicin (GO) for Patients with Relapsed Acute Myeloid Leukemia with Correlative Biomarker Studies
Ball, E. D., Medeiros, B. C., Balaian, L., Roque, T., Corringham, S., Rajwanshi, R., … Messer, K. (2010). Update of a Phase I/II Trial of 5-Azacytidine Prior to Gemtuzumab Ozogamicin (GO) for Patients with Relapsed Acute Myeloid Leukemia with Correlative Biomarker Studies. BLOOD, 116(21), 1346. -
Influence of residual normal metaphases in acute myeloid leukemia patients with monosomal karyotype
Xie, B., Othus, M., Medeiros, B. C., Fang, M., Appelbaum, F. R., & Estey, E. H. (2011). Influence of residual normal metaphases in acute myeloid leukemia patients with monosomal karyotype. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 96(4), 631–32. -
A Phase I/II Trial of 5-Azacytidine Prior to Gemtuzumab Ozogamicin (GO) for Patients with Relapsed Acute Myeloid Leukemia with Correlative Biomarker Studies.
Ball, E. D., Medeiros, B. C., Balaian, L., Roque, T., Corringham, S., Rajwanshi, R., … Messer, K. (2009). A Phase I/II Trial of 5-Azacytidine Prior to Gemtuzumab Ozogamicin (GO) for Patients with Relapsed Acute Myeloid Leukemia with Correlative Biomarker Studies. BLOOD, 114(22), 809. -
High Risk of Early Mortality in Adult Patients with Acquired Hemophagocytic Lymphohistiocytosis.
Logan, A. C., Su, R., George, T. I., Kohrt, H. E., Medeiros, B. C., & Alizadeh, A. A. (2009). High Risk of Early Mortality in Adult Patients with Acquired Hemophagocytic Lymphohistiocytosis. BLOOD, 114(22), 554. -
Tailored Temozolomide Therapy for Elderly Patients with Acute Myeloid Leukemia.
Medeiros, B. C., Gotlib, J. R., Coutre, S. E., Mignea, A., & Zehnder, J. (2008). Tailored Temozolomide Therapy for Elderly Patients with Acute Myeloid Leukemia. BLOOD, 112(11), 351. -
Chemotherapy based combinations in AML: Time to take a step back?
Medeiros, B. C. (2018). Chemotherapy based combinations in AML: Time to take a step back? Leukemia Research, 73, 39–40. -
Functional genomic landscape of acute myeloid leukaemia.
Tyner, J. W., Tognon, C. E., Bottomly, D., Wilmot, B., Kurtz, S. E., Savage, S. L., … Druker, B. J. (2018). Functional genomic landscape of acute myeloid leukaemia. Nature. -
Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial.
Bixby, D., Noppeney, R., Lin, T. L., Cortes, J., Krauter, J., Yee, K., … Colburn, D. (2018). Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial. British Journal of Haematology. -
NSAID consumption and risk of acute myeloid leukemia: a national population-based case-control study
Ostgard, L. S. G., Norgaard, M., Pedersen, L., Ostgard, R., Friis, L. S., Schollkopf, C., … Jensen, M. K. (2018). NSAID consumption and risk of acute myeloid leukemia: a national population-based case-control study. CANCER MANAGEMENT AND RESEARCH, 10, 5043–51. -
Is there a standard of care for relapsed AML?
Medeiros, B. C. (2018). Is there a standard of care for relapsed AML? Best Practice & Research. Clinical Haematology, 31(4), 384–86. -
Novel Therapeutics in Acute Myeloid Leukemia.
DiNardo, C. D., Stone, R. M., & Medeiros, B. C. (2017). Novel Therapeutics in Acute Myeloid Leukemia. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting, (37), 495–503. -
The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900).
Medeiros, B. C., Othus, M., Tallman, M. S., Sun, Z., Fernandez, H. F., Rowe, J. M., … Erba, H. P. (2019). The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900). Leukemia Research, 78, 29–33. -
Treatment patterns in patients with acute myeloid leukemia in the United States: a cross-sectional, real-world survey.
Medeiros, B. C., Pandya, B. J., Hadfield, A., Pike, J., Wilson, S., Mueller, C., … Horvath, L. E. (2019). Treatment patterns in patients with acute myeloid leukemia in the United States: a cross-sectional, real-world survey. Current Medical Research and Opinion, 1. -
Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study.
Garcia-Manero, G., Abaza, Y., Takahashi, K., Medeiros, B. C., Arellano, M., Khaled, S. K., … Atallah, E. (2019). Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. Blood Advances, 3(4), 508–18. -
Single-Cell Mutational Profiling Describes the Molecular Heterogeneity of Clonal Evolution in MDS during Therapy and Relapse
Aleshin, A., Durruthy-Durruthy, R., Medeiros, B. C., Eastburn, D. J., & Greenberg, P. L. (2018). Single-Cell Mutational Profiling Describes the Molecular Heterogeneity of Clonal Evolution in MDS during Therapy and Relapse. BLOOD, 132. -
The Relationship between Age and Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in a Cohort of Older Patients with Acute Myeloid Leukemia (AML)
Medeiros, B. C., Satram-Hoang, S., Momin, F., & Parisi, M. (2018). The Relationship between Age and Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in a Cohort of Older Patients with Acute Myeloid Leukemia (AML). BLOOD, 132. -
Dynamic BH3 Profiling Predicts for Clinical Response to Lenalidomide Plus Chemotherapy in Relapsed Acute Myeloid Leukemia
Garcia, J. S., Bhatt, S., Fell, G., Blonquist, T. M., Taw, J., Iberri, D., … Medeiros, B. C. (2018). Dynamic BH3 Profiling Predicts for Clinical Response to Lenalidomide Plus Chemotherapy in Relapsed Acute Myeloid Leukemia. BLOOD, 132. -
Increase in Chemotherapy Use and Associated Survival Benefit Among Medicare-Aged Patients with Acute Myeloid Leukemia (AML)
Medeiros, B. C., Satram-Hoang, S., Momin, F., & Parisi, M. (2018). Increase in Chemotherapy Use and Associated Survival Benefit Among Medicare-Aged Patients with Acute Myeloid Leukemia (AML). BLOOD, 132. -
Augmentation of the Acute Myeloid Leukemia-Composite Model (AML-CM) with Performance Status and Secondary Leukemia
Elsayed, S., Storer, B. E., Medeiros, B. C., Asslan, M. A., Lynch, Y., Nyland, J. E., … Sorror, M. L. (2018). Augmentation of the Acute Myeloid Leukemia-Composite Model (AML-CM) with Performance Status and Secondary Leukemia. BLOOD, 132. -
PD-L1 Blockade with Atezolizumab in Higher-Risk Myelodysplastic Syndrome: An Initial Safety and Efficacy Analysis
Gerds, A. T., Scott, B. L., Greenberg, P. L., Khaled, S. K., Lin, T. L., Pollyea, D. A., … Donnellan, W. B. (2018). PD-L1 Blockade with Atezolizumab in Higher-Risk Myelodysplastic Syndrome: An Initial Safety and Efficacy Analysis. BLOOD, 132. -
Single-Cell Mutational Profiling of Clonal Evolution in De Novo AML during Therapy and Relapse
Aleshin, A., Durruthy-Durruthy, R., Corces, M. R., Stafford, M., Liedtke, M., Medeiros, B. C., … Majeti, R. (2018). Single-Cell Mutational Profiling of Clonal Evolution in De Novo AML during Therapy and Relapse. BLOOD, 132. -
Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observational Study
Sorror, M. L., Storer, B. E., Gerds, A. T., Medeiros, B. C., Shami, P. J., Galvin, J. P., … Estey, E. H. (2018). Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observational Study. BLOOD, 132. -
Ratify (Alliance 10603): Prognostic Impact of FLT3 tyrosine Kinase Domain (TKD) and NPM1 Mutation Status in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Treated with Midostaurin or Placebo Plus Standard Chemotherapy
Voso, M. T., Larson, R. A., Prior, T., Marcucci, G., Jones, D., Krauter, J., … Lo-Coco, F. (2018). Ratify (Alliance 10603): Prognostic Impact of FLT3 tyrosine Kinase Domain (TKD) and NPM1 Mutation Status in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Treated with Midostaurin or Placebo Plus Standard Chemotherapy. BLOOD, 132. -
Longer Distance to a Specialized Treatment Center Does Not Adversely Affect Access to Treatment or Outcome in Acute Myeloid Leukemia: A National Population-Based Cohort Study
Tostesen, M. B., Norgaard, J. M., Norgaard, M., Medeiros, B. C., Marcher, C. W., Overgaard, U. M., … Oestgaard, L. S. G. (2018). Longer Distance to a Specialized Treatment Center Does Not Adversely Affect Access to Treatment or Outcome in Acute Myeloid Leukemia: A National Population-Based Cohort Study. BLOOD, 132. -
Real-World Treatment Patterns and Comparative Effectiveness Among a Population of Elderly Patients with Acute Myeloid Leukemia (AML)
Medeiros, B. C., Satram-Hoang, S., Momin, F., & Parisi, M. (2018). Real-World Treatment Patterns and Comparative Effectiveness Among a Population of Elderly Patients with Acute Myeloid Leukemia (AML). BLOOD, 132. -
Comprehensive Molecular Profiling of FLT3-Mutated Acute Myeloid Leukemia (AML) Patients Treated within the Ratify Trial (Alliance C10603)
Jahn, N., Panina, E., Bullinger, L., Dolnik, A., Herzig, J., Blaette, T. J., … Doehner, K. (2018). Comprehensive Molecular Profiling of FLT3-Mutated Acute Myeloid Leukemia (AML) Patients Treated within the Ratify Trial (Alliance C10603). BLOOD, 132. -
Prognostic Impact of Insertion Site in Acute Myeloid Leukemia (AML) with FLT3 Internal Tandem Duplication: Results from the Ratify Study (Alliance 10603)
Ruecker, F. G., Du, L., Blaette, T. J., Benner, A., Krzykalla, J., Gathmann, I., … Dohner, K. (2018). Prognostic Impact of Insertion Site in Acute Myeloid Leukemia (AML) with FLT3 Internal Tandem Duplication: Results from the Ratify Study (Alliance 10603). BLOOD, 132. -
Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: A Large Real-Time Multi-Center Prospective Longitudinal Observational Study
Sorror, M. L., Storer, B. E., Gerds, A. T., Medeiros, B. C., Shami, P. J., Galvin, J. P., … Estey, E. H. (2018). Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: A Large Real-Time Multi-Center Prospective Longitudinal Observational Study. BLOOD, 132. -
Addressing the Room for Improvement in Management of Acute Promyelocytic Leukemia.
Norgaard, J. M., Friis, L. S., Kristensen, J. S., Severinsen, M. T., Molle, I., Marcher, C. W., … Ostgard, L. S. (2019). Addressing the Room for Improvement in Management of Acute Promyelocytic Leukemia. European Journal of Haematology. -
National Survey of Pathologists on the Application of Ancillary Testing in the Diagnosis of Acute Myeloid Leukemia
Hasserjian, R., Altman, J., Denzen, E., Block, A. M., Klepin, H., Medeiros, B., … Burns, L. (2018). National Survey of Pathologists on the Application of Ancillary Testing in the Diagnosis of Acute Myeloid Leukemia. LABORATORY INVESTIGATION, 98, 520. -
Overall survival (OS) and stem cell transplant (SCT) in patients with FLT3 mutations treated with CPX-351 versus 7+3: Subgroup analysis of a phase III study of older adults with newly diagnosed, high-risk acute myeloid leukemia (AML).
Medeiros, B. C., Hogge, D., Newell, L. F., Bixby, D. L., Solomon, S. R., Strickland, S. A., … Lancet, J. E. (2017). Overall survival (OS) and stem cell transplant (SCT) in patients with FLT3 mutations treated with CPX-351 versus 7+3: Subgroup analysis of a phase III study of older adults with newly diagnosed, high-risk acute myeloid leukemia (AML). JOURNAL OF CLINICAL ONCOLOGY, 35. -
Real-world prescribing patterns in acute myeloid leukemia in the United States.
Medeiros, B. C., Pandya, B. J., Hadfield, A., Wilson, S., Mueller, C., Bailey, T., … Rider, A. (2017). Real-world prescribing patterns in acute myeloid leukemia in the United States. JOURNAL OF CLINICAL ONCOLOGY, 35. -
Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML): Results of a phase I dose-escalation and expansion study.
Stein, E. M., Dinardo, C. D., Pollyea, D. A., Fathi, A. T., Roboz, G. J., Altman, J. K., … Tallman, M. S. (2017). Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML): Results of a phase I dose-escalation and expansion study. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia.
Medeiros, B. C., Chan, S. M., Daver, N. G., Jonas, B. A., & Pollyea, D. A. (2019). Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. American Journal of Hematology. -
NSAID consumption and risk of acute myeloid leukemia: a national population-based case-control study.
Østgård, L. S., Nørgaard, M., Pedersen, L., Østgård, R., Friis, L. S., Schöllkopf, C., … Jensen, M. K. (2018). NSAID consumption and risk of acute myeloid leukemia: a national population-based case-control study. Cancer Management and Research, 10, 5043–5051. -
Quality of life of acute myeloid leukemia patients in a real-world setting.
Pandya, B. J., Hadfield, A., Medeiros, B. C., Wilson, S., Bui, C. N., Bailey, T., … Horvath, L. E. (2017). Quality of life of acute myeloid leukemia patients in a real-world setting. JOURNAL OF CLINICAL ONCOLOGY, 35. -
Correlation between mutation clearance and clinical response in elderly patients with acute myeloid leukemia (AML) treated with azacitidine and pracinostat.
Takahashi, K., Abaza, Y., Atallah, E. L., Medeiros, B. C., Khal, S., Arellano, M. L., … Garcia-Manero, G. (2017). Correlation between mutation clearance and clinical response in elderly patients with acute myeloid leukemia (AML) treated with azacitidine and pracinostat. JOURNAL OF CLINICAL ONCOLOGY, 35. -
Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial
Bixby, D., Noppeney, R., Lin, T. L., Cortes, J., Krauter, J., Yee, K., … Colburn, D. (2019). Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial. BRITISH JOURNAL OF HAEMATOLOGY, 185(3), 595–98. -
Functional genomic landscape of acute myeloid leukaemia
Tyner, J. W., Tognon, C. E., Bottomly, D., Wilmot, B., Kurtz, S. E., Savage, S. L., … Druker, B. J. (2018). Functional genomic landscape of acute myeloid leukaemia. NATURE, 562(7728), 526-+. -
Treatment patterns in patients with acute myeloid leukemia in the United States: a cross-sectional, real-world survey
Medeiros, B. C., Pandya, B. J., Hadfield, A., Pike, J., Wilson, S., Mueller, C., … Walsh, L. E. H. (2019). Treatment patterns in patients with acute myeloid leukemia in the United States: a cross-sectional, real-world survey. CURRENT MEDICAL RESEARCH AND OPINION, 35(5), 927–35. -
Recurrent drug sensitivity patterns in myelodysplastic syndrome patients are recapitulated by ex vivo drug response profiling
Aleshin, A., Medeiros, B. C., Kamble, S., Heiser, D., Santaguida, M., Prashad, S., & Greenberg, P. L. (2018). Recurrent drug sensitivity patterns in myelodysplastic syndrome patients are recapitulated by ex vivo drug response profiling. CANCER RESEARCH, 78(13). -
Real-World Impact of Physician and Patient Discordance on Health-Related Quality of Life in US Patients with Acute Myeloid Leukemia
Walsh, L. E. H., Rider, A., Piercy, J., Pike, J., Wilson, S., Pandya, B. J., & Medeiros, B. C. (2019). Real-World Impact of Physician and Patient Discordance on Health-Related Quality of Life in US Patients with Acute Myeloid Leukemia. ONCOLOGY AND THERAPY, 7(1), 67–81. -
Single-cell mutational profiling of clonal evolution in myelodysplastic syndromes (MDS) during therapy and disease progression
Aleshin, A., Greenberg, P. L., Medeiros, B. C., Heiser, D., Santaguida, M., Prashad, S., … Eastburn, D. J. (2018). Single-cell mutational profiling of clonal evolution in myelodysplastic syndromes (MDS) during therapy and disease progression. CANCER RESEARCH, 78(13). -
Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia
Medeiros, B. C., Chan, S. M., Daver, N. G., Jonas, B. A., & Pollyea, D. A. (2019). Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. AMERICAN JOURNAL OF HEMATOLOGY, 94(7), 803–11. -
Economic and Clinical Burden of Relapsed and/or Refractory Active Treatment Episodes in Patients with Acute Myeloid Leukemia (AML) in the USA: A Retrospective Analysis of a Commercial Payer Database.
Pandya, B. J., Chen, C.-C., Medeiros, B. C., McGuiness, C. B., Wilson, S., Horvath Walsh, L. E., & Wade, R. L. (2019). Economic and Clinical Burden of Relapsed and/or Refractory Active Treatment Episodes in Patients with Acute Myeloid Leukemia (AML) in the USA: A Retrospective Analysis of a Commercial Payer Database. Advances in Therapy. -
Addressing the room for improvement in management of acute promyelocytic leukemia
Norgaard, J. M., Friis, L. S., Kristensen, J. S., Severinsen, M. T., Molle, I., Marcher, C. W., … Ostgard, L. S. G. (2019). Addressing the room for improvement in management of acute promyelocytic leukemia. EUROPEAN JOURNAL OF HAEMATOLOGY, 102(6), 479–85. -
Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study
Garcia-Manero, G., Abaza, Y., Takahashi, K., Medeiros, B. C., Arellano, M., Khaled, S. K., … Atallah, E. (2019). Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. BLOOD ADVANCES, 3(4), 508–18. -
The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900)
Medeiros, B. C., Othus, M., Tallman, M. S., Sun, Z., Fernandez, H. F., Rowe, J. M., … Erba, H. P. (2019). The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900). LEUKEMIA RESEARCH, 78, 29–33. -
Is there a standard of care for relapsed AML?
Medeiros, B. C. (2018). Is there a standard of care for relapsed AML? BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 31(4), 384–86. -
Chemotherapy based combinations in AML: Time to take a step back?
Medeiros, B. C. (2018). Chemotherapy based combinations in AML: Time to take a step back? LEUKEMIA RESEARCH, 73, 39–40. -
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
Lancet, J. E., Uy, G. L., Cortes, J. E., Newell, L. F., Lin, T. L., Ritchie, E. K., … Medeiros, B. C. (2018). CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. JOURNAL OF CLINICAL ONCOLOGY, 36(26), 2684-+. -
Efficacy by consolidation administration site: Subgroup analysis of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed, high-risk acute myeloid leukemia (AML).
Kolitz, J. E., Strickland, S. A., Cortes, J. E., Hogge, D., Lancet, J. E., Goldberg, S. L., … Medeiros, B. C. (2017). Efficacy by consolidation administration site: Subgroup analysis of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed, high-risk acute myeloid leukemia (AML). JOURNAL OF CLINICAL ONCOLOGY, 35. -
Optimizing infusion scheduling through lean methods and data science.
Medeiros, B. C., Healy, D., Seshadri, S. B., Rosenthal, E. L., Martin, J., Giridharadas, M., … DeMarco, S. (2016). Optimizing infusion scheduling through lean methods and data science. JOURNAL OF CLINICAL ONCOLOGY, 34(15). -
Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML.
Lancet, J. E., Uy, G. L., Cortes, J. E., Newell, L. F., Lin, T. L., Ritchie, E. K., … Medeiros, B. C. (2016). Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML. JOURNAL OF CLINICAL ONCOLOGY, 34(15). -
Qualitative Analysis of Practicing Oncologists' Attitudes and Experiences Regarding Collection of Patient-Reported Outcomes
Jagsi, R., Chiang, A., Polite, B. N., Medeiros, B. C., McNiff, K., Abernethy, A. P., … Loehrer, P. J. (2013). Qualitative Analysis of Practicing Oncologists' Attitudes and Experiences Regarding Collection of Patient-Reported Outcomes. JOURNAL OF ONCOLOGY PRACTICE, 9(6), E290–E297. -
Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin.
Narayan, R., Olsson, N., Wagar, L. E., Medeiros, B. C., Meyer, E., Czerwinski, D., … Levy, R. (2019). Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin. PloS One, 14(7), e0219547. -
Genomic landscape of Neutrophilic Leukemias of Ambiguous Diagnosis.
Zhang, H., Wilmot, B., Bottomly, D., Dao, K.-H. T., Stevens, E., Eide, C. A., … Tyner, J. W. (2019). Genomic landscape of Neutrophilic Leukemias of Ambiguous Diagnosis. Blood. -
Longer distance to specialized treatment centers does not adversely affect treatment intensity or outcomes in adult acute myeloid leukemia patients. A Danish national population-based cohort study
Tostesen, M., Norgaard, M., Norgaard, J. M., Medeiros, B. C., Marcher, C. W., Overgaard, U. M., … Ostgard, L. S. G. (2019). Longer distance to specialized treatment centers does not adversely affect treatment intensity or outcomes in adult acute myeloid leukemia patients. A Danish national population-based cohort study. CLINICAL EPIDEMIOLOGY, 11, 769–80. -
Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia.
DeAngelo, D. J., Walker, A. R., Schlenk, R. F., Sierra, J., Medeiros, B. C., Ocio, E. M., … Stuart, R. K. (2019). Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia. Leukemia Research, 85, 106197. -
Longer distance to specialized treatment centers does not adversely affect treatment intensity or outcomes in adult acute myeloid leukemia patients. A Danish national population-based cohort study.
Tøstesen, M., Nørgaard, M., Nørgaard, J. M., Medeiros, B. C., Marcher, C. W., Overgaard, U. M., … Østgård, L. S. (2019). Longer distance to specialized treatment centers does not adversely affect treatment intensity or outcomes in adult acute myeloid leukemia patients. A Danish national population-based cohort study. Clinical Epidemiology, 11, 769–780. -
Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapy.
Garcia, J. S., Bhatt, S., Fell, G., Sperling, A. S., Burgess, M., Keshishian, H., … Letai, A. (2019). Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapy. American Journal of Hematology. -
Impact of NPM1/FLT3-ITD genotypes defined by the2017 European LeukemiaNet in patients with acute myeloid leukemia.
Döhner, K., Thiede, C., Jahn, N., Panina, E., Gambietz, A., Larson, R. A., … Bloomfield, C. D. (2019). Impact of NPM1/FLT3-ITD genotypes defined by the2017 European LeukemiaNet in patients with acute myeloid leukemia. Blood. -
Functional characterization of two rare BCR-FGFR1+ leukemias.
Barnes, E. J., Leonard, J., Medeiros, B., Druker, B. J., & Tognon, C. E. (2020). Functional characterization of two rare BCR-FGFR1+ leukemias. Cold Spring Harbor Molecular Case Studies. -
Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia.
Pagel, J. M., Othus, M., Garcia-Manero, G., Fang, M., Radich, J. P., Rizzieri, D. A., … Appelbaum, F. R. (2020). Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia. JCO Oncology Practice, JOP1900133. -
Single-cell mutational profiling enhances the clinical evaluation of AML MRD.
Ediriwickrema, A., Aleshin, A., Reiter, J. G., Corces, M. R., Köhnke, T., Stafford, M., … Majeti, R. (2020). Single-cell mutational profiling enhances the clinical evaluation of AML MRD. Blood Advances, 4(5), 943–52. -
Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database.
Pandya, B. J., Chen, C.-C., Medeiros, B. C., McGuiness, C. B., Wilson, S. D., Walsh, E. H., & Wade, R. L. (2020). Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database. Journal of Managed Care & Specialty Pharmacy, 1–11. -
Outcomes by number of induction cycles with CPX-351 vs 7+3 chemotherapy in older adults with newly diagnosed, high-risk/secondary acute myeloid leukemia (sAML).
Lin, T. L., Medeiros, B. C., Uy, G. L., Newell, L. F., Ritchie, E. K., Stuart, R. K., … Cortes, J. E. (2018). Outcomes by number of induction cycles with CPX-351 vs 7+3 chemotherapy in older adults with newly diagnosed, high-risk/secondary acute myeloid leukemia (sAML). JOURNAL OF CLINICAL ONCOLOGY, 36(15). -
Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience.
Azizi, A., Ediriwickrema, A., Dutta, R., Patel, S. A., Shomali, W., Medeiros, B., … Zhang, T. (2020). Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience. Leukemia & Lymphoma, 1–8. -
Real-World Impact of Physician and Patient Discordance on Health-Related Quality of Life in US Patients with Acute Myeloid Leukemia.
Horvath Walsh, L. E., Rider, A., Piercy, J., Pike, J., Wilson, S., Pandya, B. J., & Medeiros, B. C. (2019). Real-World Impact of Physician and Patient Discordance on Health-Related Quality of Life in US Patients with Acute Myeloid Leukemia. Oncology and Therapy, 7(1), 67–81. -
Analysis of Transplantation Rate and Overall Treatment Efficacy by Age for Patients Aged 60 to 75 with Untreated Secondary Acute Myeloid Leukemia (AML) Given CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial
Lancet, J., Uy, G. L., Cortes, J., Newell, L. F., Lin, T. L., Ritchie, E., … Medeiros, B. C. (2017). Analysis of Transplantation Rate and Overall Treatment Efficacy by Age for Patients Aged 60 to 75 with Untreated Secondary Acute Myeloid Leukemia (AML) Given CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 23(3), S31–S32. -
Epidemiology and impact of preceding or underlying disease in secondary acute myeloid leukemia
Ostgard, L. S. G., & Medeiros, B. C. (2018). Epidemiology and impact of preceding or underlying disease in secondary acute myeloid leukemia. HEMASPHERE, 2, 153–55. -
Multicenter 11-Year Experience of Outcomes After Intensive Versus Less-Intensive Therapy for Patients with Acute Myeloid Leukemia: Focus on Older and Medically Infirm Patients
Sorror, M., Storer, B., Fathi, A., Brunner, A., Gerds, A., Sekeres, M., … Estey, E. (2020). Multicenter 11-Year Experience of Outcomes After Intensive Versus Less-Intensive Therapy for Patients with Acute Myeloid Leukemia: Focus on Older and Medically Infirm Patients. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP. -
Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial.
Voso, M. T., Larson, R. A., Jones, D., Marcucci, G., Prior, T., Krauter, J., … Lo-Coco, F. (2020). Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. Blood Advances, 4(19), 4945–54. -
Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observational Study
Sorror, M. L., Storer, B. E., Gerds, A. T., Medeiros, B. C., Shami, P. J., Galvin, J. P., … Estey, E. H. (2019). Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observational Study. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 25(3). -
Overall Survival (OS) by Outpatient versus Inpatient Consolidation in a Phase 3 Study of CPX-351 versus 7+3 in Older Adults with Newly Diagnosed, High-Risk Acute Myeloid Leukemia (AML)
Kolitz, J., Strickland, S., Cortes, J., Hogge, D., Lancet, J., Goldberg, S., … Medeiros, B. (2017). Overall Survival (OS) by Outpatient versus Inpatient Consolidation in a Phase 3 Study of CPX-351 versus 7+3 in Older Adults with Newly Diagnosed, High-Risk Acute Myeloid Leukemia (AML). CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 17, S287. -
Overall Survival (OS) and Stem Cell Transplant (SCT) in Patients with FLT3 Mutations Treated with CPX-351 versus 7+3: Subgroup Analysis of a Phase 3 Study of Older Adults with Newly Diagnosed, High-Risk Acute Myeloid Leukemia (AML)
Medeiros, B., Hogge, D., Newell, L., Bixby, D., Solomon, S., Strickland, S., … Lancet, J. (2017). Overall Survival (OS) and Stem Cell Transplant (SCT) in Patients with FLT3 Mutations Treated with CPX-351 versus 7+3: Subgroup Analysis of a Phase 3 Study of Older Adults with Newly Diagnosed, High-Risk Acute Myeloid Leukemia (AML). CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 17, S286. -
Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial.
Larson, R. A., Mandrekar, S. J., Huebner, L. J., Sanford, B. L., Laumann, K., Geyer, S., … Stone, R. M. (2021). Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. Leukemia. -
Plasma Microbial Cell-free DNA Next Generation Sequencing in the Diagnosis and Management of Febrile Neutropenia.
Benamu, E., Gajurel, K., Anderson, J. N., Lieb, T., Gomez, C. A., Seng, H., … Deresinski, S. (2021). Plasma Microbial Cell-free DNA Next Generation Sequencing in the Diagnosis and Management of Febrile Neutropenia. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. -
Multi-Site 11-Year Experience of Less-Intensive versus Intensive Therapies in Acute Myeloid Leukemia.
Sorror, M. L., Storer, B. E., Fathi, A. T., Brunner, A. M., Gerds, A. T., Sekeres, M. A., … Estey, E. H. (2021). Multi-Site 11-Year Experience of Less-Intensive versus Intensive Therapies in Acute Myeloid Leukemia. Blood. -
Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results.
Rucker, F. G., Du, L., Luck, T. J., Benner, A., Krzykalla, J., Gathmann, I., … Dohner, K. (2021). Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. Leukemia. -
Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia.
Sorror, M. L., Storer, B. E., Fathi, A. T., Brunner, A., Gerds, A. T., Sekeres, M. A., … Estey, E. H. (2021). Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia. Blood, 138(5), 387–400. -
Event free survival in adults with relapsed ALL who underwent front-line therapy with CALGB 10403.
Raychaudhuri, S., Yurkiewicz, I., Mannis, G. N., Medeiros, B. C., Coutre, S. E., Muffly, L. S., & Liedtke, M. (2021). Event free survival in adults with relapsed ALL who underwent front-line therapy with CALGB 10403. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome.
Gerds, A. T., Scott, B. L., Greenberg, P. L., Lin, T. L., Pollyea, D. A., Verma, A. K., … Donnellan, W. B. (1800). Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome. Blood Advances. -
Epidemiology of invasive fungal diseases in adults with newly diagnosed acute myeloid leukemia.
Miranti, E., Ho, D. Y., Enriquez, K., Subramanian, A. K., Medeiros, B. C., & Epstein, D. J. (2022). Epidemiology of invasive fungal diseases in adults with newly diagnosed acute myeloid leukemia. Leukemia & Lymphoma, 1–7. -
Factors associated with risk and prognosis of intensive care unit admission in patients with acute leukemia: a Danish nationwide cohort study.
Maeng, C. V., Christiansen, C. F., Liu, K. D., Kamper, P., Christensen, S., Medeiros, B. C., & Ostgard, L. S. (2022). Factors associated with risk and prognosis of intensive care unit admission in patients with acute leukemia: a Danish nationwide cohort study. Leukemia & Lymphoma, 1–11. -
Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial.
Jahn, N., Jahn, E., Saadati, M., Bullinger, L., Larson, R. A., Ottone, T., … Döhner, K. (2022). Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial. Leukemia. -
An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm AML patients.
Sorror, M. L., Gooley, T. A., Storer, B. E., Gerds, A. T., Sekeres, M. A., Medeiros, B. C., … Estey, E. (2022). An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm AML patients. Blood. -
Novel Data Analytics Identify Predictors of Quality-of-Life Trajectories in Patients with AML or High-Risk Myeloid Neoplasms
Gauthier, J., Furtuna, B., Mangiavacchi, J., Gholami, S., Ferres, J. L., Dodhia, R., … Sorror, M. L. (2022). Novel Data Analytics Identify Predictors of Quality-of-Life Trajectories in Patients with AML or High-Risk Myeloid Neoplasms. BLOOD. AMER SOC HEMATOLOGY. -
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML.
Garcia-Manero, G., Podoltsev, N. A., Othus, M., Pagel, J. M., Radich, J. P., Fang, M., … Erba, H. P. (2023). A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML. Leukemia.
Practice Locations
SHC- Hematology Palo Alto, CA
Palo Alto, CAImportant Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(67 reviews)
View More »
Referring Physicians
PHYSICIAN HELPLINE
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records